Sector
PharmaceuticalsOpen
₹8.3Prev. Close
₹8.3Turnover(Lac.)
₹0.04Day's High
₹8.3Day's Low
₹8.352 Week's High
₹8.352 Week's Low
₹3.18Book Value
₹2.46Face Value
₹10Mkt Cap (₹ Cr.)
3.64P/E
0EPS
0Divi. Yield
02 Sep 2023
12:00 AM
AGM
Announcement Date: 02 Sep, 2023
4 Sep 2023
12:00 AM
BookCloser
6 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
23 Jan 2024
12:00 AM
EGM
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 4.39 | 4.39 | 4.39 | 4.39 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.12 | -4.78 | -4.6 | -4.42 |
Net Worth | -0.73 | -0.39 | -0.21 | -0.03 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 1.8 |
yoy growth (%) | 0 | 0 | -100 | -76.3 |
Raw materials | 0 | 0 | 0 | -1.27 |
As % of sales | 0 | 0 | 0 | 70.86 |
Employee costs | -0.04 | 0 | -0.03 | -1.17 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | -0.18 | -0.05 | -0.16 | -1.41 |
Depreciation | -0.03 | -0.03 | -0.03 | -0.13 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.1 | 0 | -0.12 | -0.9 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | -100 | -76.3 |
Op profit growth | 198.36 | -63.66 | -86.72 | -334.74 |
EBIT growth | 207.45 | -63.16 | -86.27 | -477.56 |
Net profit growth | 202.1 | -63.82 | -93 | -1,909.97 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,587.9 | 124.83 | 3,80,990.4 | 867.6 | 0.85 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,534.75 | 76.42 | 1,20,383.36 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,489.7 | 32.38 | 1,20,295.96 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,154.4 | 33.79 | 1,16,159.65 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,769.25 | 26.36 | 1,12,931.2 | 1,034.8 | 0.59 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director & CFO
B V Anatha Kumar
Independent Director
Ananthkumar Shilpa
Independent Director
Churchil Durai M Jebastine
Independent Director
KUNIAMUTHUR NANJAPPAN ANAND
Company Sec. & Compli. Officer
Monika Sanwal
Independent Director
A Anitha
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kabra Drugs Ltd
Summary
Kabra Drugs Ltd was incorporated as a Limited Company on August 22, 1989. The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical. The commercial production commenced in 1991. Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P. tHE Company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.The latest addition to the product line is the range of disinfectants which includes hand wash gel, hand sanitizer and antimicrobial gel. In India there are very few manufacturers who are manufacturing the said products. The company is the sole manufacturer of antimicrobial hand wash gel and other disinfectant products in India. The company is also a registered supplier to the Ministry of Defence.With manufacturing and regular supply in the domestic market for injectables, soft gelatin capsules and liquids (oral and external especially alcohol products) the company now looks at the global market. A number of new products have been developed for the same.Kabra Drugs are known to meet the diverse medical needs of patients in Emerging Markets in an innovative, socially responsible and commercially viable manner. Their products are manufactured at state of the art ultra modern plants with latest equipments backed by professional technocrats. These are WHO-GMP, cGMP & Sched
Read More
What is the Kabra Drugs Ltd share price today?
The Kabra Drugs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹8.3 today.
What is the Market Cap of Kabra Drugs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kabra Drugs Ltd is ₹3.64 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Kabra Drugs Ltd?
The PE and PB ratios of Kabra Drugs Ltd is 0 and 3.37 as of 22 Jul ‘24
What is the 52 Week High and Low of Kabra Drugs Ltd?
The 52-week high/low is the highest and lowest price at which a Kabra Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kabra Drugs Ltd is ₹3.18 and ₹8.3 as of 22 Jul ‘24
What is the CAGR of Kabra Drugs Ltd?
Kabra Drugs Ltd's CAGR for 5 Years at 68.56%, 3 Years at 16.49%, 1 Year at 54.56%, 6 Month at 27.11%, 3 Month at 15.44% and 1 Month at 4.93%.
What is the shareholding pattern of Kabra Drugs Ltd?
The shareholding pattern of Kabra Drugs Ltd is as follows:
Promoters - 0.00 %
Institutions - 0.00 %
Public - 100.00 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
